Cantor Fitzgerald Has Positive View of CATX FY2024 Earnings

Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) - Cantor Fitzgerald boosted their FY2024 EPS estimates for Perspective Therapeutics in a report released on Wednesday, November 13th. Cantor Fitzgerald analyst L. Chen now anticipates that the company will post earnings per share of ($0.90) for the year, up from their prior forecast of ($0.95). Cantor Fitzgerald currently has a "Overweight" rating on the stock. The consensus estimate for Perspective Therapeutics' current full-year earnings is ($0.86) per share.

CATX has been the topic of a number of other research reports. Royal Bank of Canada cut their price target on shares of Perspective Therapeutics from $29.00 to $27.00 and set an "outperform" rating on the stock in a report on Friday, August 16th. Bank of America started coverage on Perspective Therapeutics in a research note on Thursday, July 25th. They set a "buy" rating and a $24.00 price target on the stock. Wedbush reaffirmed an "outperform" rating and issued a $20.00 price target on shares of Perspective Therapeutics in a research note on Thursday, October 24th. UBS Group initiated coverage on Perspective Therapeutics in a research note on Thursday, October 24th. They issued a "buy" rating and a $20.00 price objective on the stock. Finally, Truist Financial assumed coverage on Perspective Therapeutics in a research note on Wednesday, September 25th. They set a "buy" rating and a $21.00 price target for the company. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of "Buy" and an average price target of $21.57.

Perspective Therapeutics Stock Down 11.8 %

CATX stock traded down $0.93 during mid-day trading on Monday, reaching $6.95. 1,501,748 shares of the company traded hands, compared to its average volume of 698,649. The company has a fifty day moving average price of $12.55. Perspective Therapeutics has a 52-week low of $2.28 and a 52-week high of $19.05.

Perspective Therapeutics (NYSE:CATX - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.21) earnings per share for the quarter, meeting the consensus estimate of ($0.21). Perspective Therapeutics had a negative net margin of 4,096.66% and a negative return on equity of 27.40%. The firm had revenue of $0.37 million for the quarter.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in CATX. Janus Henderson Group PLC purchased a new position in Perspective Therapeutics in the first quarter valued at $15,511,000. FMR LLC lifted its stake in shares of Perspective Therapeutics by 3,994.9% during the 3rd quarter. FMR LLC now owns 5,504,822 shares of the company's stock worth $73,489,000 after purchasing an additional 5,370,392 shares during the period. Affinity Asset Advisors LLC acquired a new position in Perspective Therapeutics during the 1st quarter worth approximately $6,069,000. Vanguard Group Inc. boosted its holdings in shares of Perspective Therapeutics by 34.6% in the 1st quarter. Vanguard Group Inc. now owns 17,780,106 shares of the company's stock valued at $21,158,000 after buying an additional 4,566,356 shares during the period. Finally, Nicholson Wealth Management Group LLC bought a new stake in shares of Perspective Therapeutics in the 3rd quarter worth $21,390,000. Institutional investors own 54.66% of the company's stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.